Literature DB >> 32820016

Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.

Charles Marusak1, Varsha Thakur1, Yuan Li1, Juliano T Freitas1, Patrick M Zmina1, Vijay S Thakur2, Mayland Chang3, Ming Gao3, Jiufeng Tan4, Min Xiao4, Yiling Lu5, Gordon B Mills6, Keith Flaherty7, Dennie T Frederick8, Benchun Miao8, Ryan J Sullivan8, Tabea Moll9, Genevieve M Boland9, Meenhard Herlyn4, Gao Zhang10, Barbara Bedogni11.   

Abstract

PURPOSE: The extracellular matrix (ECM) is an intriguing, yet understudied component of therapy resistance. Here, we investigated the role of ECM remodeling by the collagenase, MT1-MMP, in conferring resistance of v-Raf murine sarcoma viral oncogene homolog B1 (BRAF)-mutant melanoma to BRAF inhibitor (BRAFi) therapy. EXPERIMENTAL
DESIGN: Publicly available RNA-sequencing data and reverse phase protein array were used to determine the relevance of MT1-MMP upregulation in BRAFi-resistant melanoma in patients, patient-derived xenografts, and cell line-derived tumors. Short hairpin RNA (shRNA)-mediated knockdown of MT1-MMP, inhibition via the selective MT1-MMP/MMP2 inhibitor, ND322, or overexpression of MT1-MMP was used to assess the role of MT1-MMP in mediating resistance to BRAFi.
RESULTS: MT1-MMP was consistently upregulated in posttreatment tumor samples derived from patients upon disease progression and in melanoma xenografts and cell lines that acquired resistance to BRAFi. shRNA- or ND322-mediated inhibition of MT1-MMP synergized with BRAFi leading to resensitization of resistant cells and tumors to BRAFi. The resistant phenotype depends on the ability of cells to cleave the ECM. Resistant cells seeded in MT1-MMP uncleavable matrixes were resensitized to BRAFi similarly to MT1-MMP inhibition. This is due to the inability of cells to activate integrinβ1 (ITGB1)/FAK signaling, as restoration of ITGB1 activity is sufficient to maintain resistance to BRAFi in the context of MT1-MMP inhibition. Finally, the increase in MT1-MMP in BRAFi-resistant cells is TGFβ dependent, as inhibition of TGFβ receptors I/II dampens MT1-MMP overexpression and restores sensitivity to BRAF inhibition.
CONCLUSIONS: BRAF inhibition results in a selective pressure toward higher expression of MT1-MMP. MT1-MMP is pivotal to an ECM-based signaling pathway that confers resistance to BRAFi therapy. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32820016      PMCID: PMC7669662          DOI: 10.1158/1078-0432.CCR-19-2773

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  59 in total

1.  The membrane tethered matrix metalloproteinase MT1-MMP triggers an outside-in DNA damage response that impacts chemo- and radiotherapy responses of breast cancer.

Authors:  Varsha Thakur; Keman Zhang; Alyssa Savadelis; Patrick Zmina; Brittany Aguila; Scott M Welford; Fadi Abdul-Karim; Kristen W Bonk; Ruth A Keri; Barbara Bedogni
Journal:  Cancer Lett       Date:  2018-11-29       Impact factor: 8.679

2.  Evidence of MTCBP-1 interaction with the cytoplasmic domain of MT1-MMP: Implications in the autophagy cell index of high-grade glioblastoma.

Authors:  Jonathan Pratt; Mustapha Iddir; Steve Bourgault; Borhane Annabi
Journal:  Mol Carcinog       Date:  2015-01-15       Impact factor: 4.784

3.  PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.

Authors:  Kim H T Paraiso; Yun Xiang; Vito W Rebecca; Ethan V Abel; Y Ann Chen; A Cecilia Munko; Elizabeth Wood; Inna V Fedorenko; Vernon K Sondak; Alexander R A Anderson; Antoni Ribas; Maurizia Dalla Palma; Katherine L Nathanson; John M Koomen; Jane L Messina; Keiran S M Smalley
Journal:  Cancer Res       Date:  2011-02-11       Impact factor: 12.701

4.  The Wnt/planar cell polarity protein-tyrosine kinase-7 (PTK7) is a highly efficient proteolytic target of membrane type-1 matrix metalloproteinase: implications in cancer and embryogenesis.

Authors:  Vladislav S Golubkov; Alexei V Chekanov; Piotr Cieplak; Alexander E Aleshin; Andrei V Chernov; Wenhong Zhu; Ilian A Radichev; Danhua Zhang; P Duc Dong; Alex Y Strongin
Journal:  J Biol Chem       Date:  2010-09-13       Impact factor: 5.157

5.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Authors:  Ramin Nazarian; Hubing Shi; Qi Wang; Xiangju Kong; Richard C Koya; Hane Lee; Zugen Chen; Mi-Kyung Lee; Narsis Attar; Hooman Sazegar; Thinle Chodon; Stanley F Nelson; Grant McArthur; Jeffrey A Sosman; Antoni Ribas; Roger S Lo
Journal:  Nature       Date:  2010-11-24       Impact factor: 49.962

Review 6.  MT1-MMP: a tethered collagenase.

Authors:  Kenn Holmbeck; Paolo Bianco; Susan Yamada; Henning Birkedal-Hansen
Journal:  J Cell Physiol       Date:  2004-07       Impact factor: 6.384

Review 7.  Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.

Authors:  Thomas Wiesner; Heinz Kutzner; Lorenzo Cerroni; Martin C Mihm; Klaus J Busam; Rajmohan Murali
Journal:  Pathology       Date:  2016-01-18       Impact factor: 5.306

8.  COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

Authors:  Cory M Johannessen; Jesse S Boehm; So Young Kim; Sapana R Thomas; Leslie Wardwell; Laura A Johnson; Caroline M Emery; Nicolas Stransky; Alexandria P Cogdill; Jordi Barretina; Giordano Caponigro; Haley Hieronymus; Ryan R Murray; Kourosh Salehi-Ashtiani; David E Hill; Marc Vidal; Jean J Zhao; Xiaoping Yang; Ozan Alkan; Sungjoon Kim; Jennifer L Harris; Christopher J Wilson; Vic E Myer; Peter M Finan; David E Root; Thomas M Roberts; Todd Golub; Keith T Flaherty; Reinhard Dummer; Barbara L Weber; William R Sellers; Robert Schlegel; Jennifer A Wargo; William C Hahn; Levi A Garraway
Journal:  Nature       Date:  2010-11-24       Impact factor: 49.962

9.  New insight into the role of MMP14 in metabolic balance.

Authors:  Hidetoshi Mori; Ramray Bhat; Alexandre Bruni-Cardoso; Emily I Chen; Danielle M Jorgens; Kester Coutinho; Katherine Louie; Benjamin Ben Bowen; Jamie L Inman; Victoria Tecca; Sarah J Lee; Sabine Becker-Weimann; Trent Northen; Motoharu Seiki; Alexander D Borowsky; Manfred Auer; Mina J Bissell
Journal:  PeerJ       Date:  2016-07-13       Impact factor: 2.984

Review 10.  Can Integrin Agonists Have Cards to Play against Cancer? A Literature Survey of Small Molecules Integrin Activators.

Authors:  Alessandra Tolomelli; Paola Galletti; Monica Baiula; Daria Giacomini
Journal:  Cancers (Basel)       Date:  2017-07-05       Impact factor: 6.639

View more
  14 in total

1.  Anti-tumor activity of the pan-RAF inhibitor TAK-580 in combination with KPT-330 (selinexor) in multiple myeloma.

Authors:  Rikio Suzuki; Yuka Kitamura; Daisuke Ogiya; Yoshiaki Ogawa; Hiroshi Kawada; Kiyoshi Ando
Journal:  Int J Hematol       Date:  2021-11-05       Impact factor: 2.490

2.  Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAFV600E/NRASQ61K Melanoma Enhancing Tumor Growth and Metastasis in a Bioluminescent Murine Model.

Authors:  Jana Jandova; Georg T Wondrak
Journal:  J Invest Dermatol       Date:  2021-10-21       Impact factor: 7.590

Review 3.  Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies.

Authors:  Ann M Cathcart; Hannah Smith; Marilyne Labrie; Gordon B Mills
Journal:  Expert Rev Proteomics       Date:  2022-04-27       Impact factor: 4.250

4.  Plasma Exosome-Derived SENP1 May Be a Potential Prognostic Predictor for Melanoma.

Authors:  Hejuan Hu; Bai Ling; Yuhan Shi; Haohao Wu; Bingying Zhu; Yiling Meng; Guo-Ming Zhang
Journal:  Front Oncol       Date:  2021-08-05       Impact factor: 6.244

Review 5.  Cytoskeletal Remodelling as an Achilles' Heel for Therapy Resistance in Melanoma.

Authors:  Adrian Barreno; Jose L Orgaz
Journal:  Cells       Date:  2022-02-02       Impact factor: 6.600

6.  Blockade of the pro-fibrotic reaction mediated by the miR-143/-145 cluster enhances the responses to targeted therapy in melanoma.

Authors:  Bernard Mari; Sophie Tartare-Deckert; Serena Diazzi; Alberto Baeri; Julien Fassy; Margaux Lecacheur; Oskar Marin-Bejar; Christophe A Girard; Lauren Lefevre; Caroline Lacoux; Marie Irondelle; Carine Mounier; Marin Truchi; Marie Couralet; Mickael Ohanna; Alexandrine Carminati; Ilona Berestjuk; Frederic Larbret; David Gilot; Georges Vassaux; Jean-Christophe Marine; Marcel Deckert
Journal:  EMBO Mol Med       Date:  2022-02-14       Impact factor: 12.137

7.  Analysis of the expression and prognostic value of MT1-MMP, β1-integrin and YAP1 in glioma.

Authors:  Yangyang Zhai; Wei Sang; Liping Su; Yusheng Shen; Yanran Hu; Wei Zhang
Journal:  Open Med (Wars)       Date:  2022-03-09

8.  Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma.

Authors:  Claudia Capparelli; Timothy J Purwin; McKenna Glasheen; Signe Caksa; Manoela Tiago; Nicole Wilski; Danielle Pomante; Sheera Rosenbaum; Mai Q Nguyen; Weijia Cai; Janusz Franco-Barraza; Richard Zheng; Gaurav Kumar; Inna Chervoneva; Ayako Shimada; Vito W Rebecca; Adam E Snook; Kim Hookim; Xiaowei Xu; Edna Cukierman; Meenhard Herlyn; Andrew E Aplin
Journal:  Nat Commun       Date:  2022-03-16       Impact factor: 17.694

9.  Neurofibromin Deficiency and Extracellular Matrix Cooperate to Increase Transforming Potential through FAK-Dependent Signaling.

Authors:  Andrea Errico; Anna Stocco; Vincent M Riccardi; Alberto Gambalunga; Franco Bassetto; Martina Grigatti; Amedeo Ferlosio; Gianluca Tadini; Debora Garozzo; Stefano Ferraresi; Andrea Trevisan; Sandra Giustini; Andrea Rasola; Federica Chiara
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

10.  MT1-MMP-dependent ECM processing regulates laminB1 stability and mediates replication fork restart.

Authors:  Varsha Thakur; Juliano Tiburcio de Freitas; Yuan Li; Keman Zhang; Alyssa Savadelis; Barbara Bedogni
Journal:  PLoS One       Date:  2021-07-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.